{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:10:28Z","timestamp":1790784628545,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA132279"],"award-info":[{"award-number":["R21CA132279"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2017,7,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Early\u2010stage and intermediate\u2010stage nasopharyngeal cancer (NPC) generally carry a good prognosis, but for patients with recurrent, metastatic disease, options are limited. In the current study, the authors present a phase 1\/2 study to evaluate the efficacy of Epstein\u2010Barr virus (EBV)\u2010stimulated cytotoxic T\u2010lymphocyte (EBV\u2010CTL) immunotherapy in this patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Screening for patients with active, recurrent, metastatic EBV\u2010associated NPC began in February 2007, and the study was closed to accrual in January 2012. After informed consent was obtained, patients had their blood drawn to initiate manufacturing of the EBV\u2010CTL product. During product manufacturing, patients were placed on interim standard\u2010of\u2010care chemotherapy, and only after disease progression on the interim chemotherapy did patients receive investigational immunotherapy. Patients were restaged every 2 months until disease progression and then followed for survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A total of 28 patients were enrolled, and 21 patients were treated. There was 1 complete response achieved, and at the time of last follow\u2010up, the patient had been in remission for &gt;8 years since treatment. The median progression\u2010free survival was 2.2 months, and the median overall survival was 16.7 months. Two other patients, after failing EBV\u2010CTL immunotherapy, unexpectedly demonstrated strong responses to the chemotherapy regimens they had previously failed. Patient EBV viral load and EBV\u2010CTL specificity for tumor\u2010associated viral antigens did not appear to correlate with clinical response.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>A durable response was observed with EBV\u2010CTL immunotherapy, but the overall response rate for patients with recurrent, metastatic NPC was low. Further research is necessary to increase the efficacy of EBV\u2010specific immunotherapy in patients with incurable NPC, and to characterize mechanisms for refacilitation to chemotherapy. <jats:bold><jats:italic>Cancer<\/jats:italic> 2017;123:2642\u201050<\/jats:bold>. \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30541","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T12:43:46Z","timestamp":1487681026000},"page":"2642-2650","source":"Crossref","is-referenced-by-count":92,"title":["Epstein\u2010Barr virus\u2010specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma"],"prefix":"10.1002","volume":"123","author":[{"given":"Julian","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fogg","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Department of Medicine, Brigham and Women's Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Daley","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute, Harvard Medical School Boston Massachusetts"},{"name":"Cancer Vaccine Center Dana\u2010Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall R.","family":"Posner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred C.","family":"Wang","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Department of Medicine, Brigham and Women's Hospital Boston Massachusetts"},{"name":"Department of Microbiology and Immunobiology Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen H.","family":"Lorch","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.9347"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3399"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050512"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00280-9"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008390929826"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.9.1675"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf200"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20804"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.09.008"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.08.012"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf179"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00367-8"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07269-3"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1449::AID-CNCR3>3.0.CO;2-4"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/mp.53.5.248"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910320504"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910390106"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199710)183:2<164::AID-PATH919>3.0.CO;2-J"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509143331103"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1430"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh027"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6195"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2975"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181f3cbf4"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813320106"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.5.2689-2697.1992"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-69-5-1051"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.09.004"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.03.016"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.242"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:59:40Z","timestamp":1760284780000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,7,15]]}},"alternative-id":["10.1002\/cncr.30541"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30541","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}